Ablative Solutions Receives U.S. Patent For Peregrine System™ Infusion Catheter

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KALAMAZOO, Mich., June 11, 2014 /PRNewswire/ -- Ablative Solutions, Inc., a privately-held clinical stage company, announced today the issuance of U.S. Patent No. 8,740,849, entitled "Peri-Vascular Tissue Ablation Catheter with Support Structures." Some aspects of the issued patent relate to unique micro-needle-equipped catheters for the precise delivery of fluids into a variety of tissue targets. For example, the catheters can be used in peri-vascular or peri-urethral applications for the ablation of tissue.

"We are delighted to expand our intellectual property portfolio with this new U.S. patent. It is important to our corporate strategy, as it creates a barrier to entry and solidifies ASI's position as the emerging leader in site-specific and precise delivery of medications," noted Vartan Ghazarossian, PhD, President of Ablative Solutions. "This patent is significant, as it protects central elements of our fluid-delivery technology and could suggest our receiving additional protection from other patent applications currently under review."

About ASI
Ablative Solutions was founded in 2011 by Tim Fischell, MD, FACC, and David Fischell, PhD, and is headquartered in Kalamazoo, MI, with offices in Menlo Park, CA. Ablative Solutions has developed endovascular catheters that are designed to address life-threatening diseases by providing a durable and cost-effective means for the targeted delivery of diagnostic and therapeutic agents to the perivascular space of blood vessels.

Forward-Looking Statements
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the Company's products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company's securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. Except as required by law, the Company assumes no obligation to update the forward-looking statements, which are made as of the date hereof, even if new information becomes available in the future.

For more information:
Vartan Ghazarossian, PhD
(650) 321-6884

SOURCE Ablative Solutions, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news